The Experiences of TEVAR after Frozenix-Open Stent Graft (F-OSG) Placement for TAA Surgery~Availability of Hybrid TEVAR~
- #HS 01-O-3
- Hybrid Surgery. SESSION-1
- Oral
The Experiences of TEVAR after Frozenix-Open Stent Graft (F-OSG) Placement for TAA Surgery~Availability of Hybrid TEVAR~
Tatsuya Nakao
Asian Soceity for Cardiovascular and Thoracic Surgery, Cardiothoracic Surgery Network, Matsudo, Japan
Date, time and location: 2018.05.26 13:30, Congress Hall, 2F–A
Abstract
METHODS: Between July 2014 and July 2017, 88 patients (mean age 70.0 years, male/female 68/20) with different pathologies from the aortic arch to the extended descending aorta in 47 dissections (acute /chronic A=26/4, acute/chronic/subacute B=1/6/10) and 41 thoracic arteriosclerotic aneurysms (TAAs) had the FET technique with F-OSG performed upon them.
RESULTS: Operative mortality within 30 days was 4.5%(4 cases) due to broad CI(12d), LOS(0d), MOF(1d), TAAA rupture(13d). Late mortality was 4.5%(4 cases) due to pneumonia(6M), DIC(9M), unknown(4M), TAAA rupture(10M). During the mean follow up period of 9.7 months, the survival rate was 89.0 % at 1year. In 11 patients(pts) with stent-graft-related event, the 2nd stage TEVAR (Hybrid TEVAR) were performed. The causes of 11 pts were Mega aorta in 1 pt, dilatation of des.Ao in 4 pts, re-dissection of des.Ao in 2pts, type 1b endleak(EL)+migration in 3 pts, type 2 EL(Lt SCA) in 1 pt. 9 of 11 pts were treated succcesfully by 2nd stage TEVAR.1 pt with mega-aorta extending from the ascending-aorta to the TAAA was successfully treated by staged operations and 1 pt with type 2 EL was treated by des.Ao replacement. Residual 9pts were treated A follow-up computed tomographic image was available for 95.8% (84/88) of pts. In 39 pts with TAAs and 45 pts with dissections, Regarding the size of aneurysm and false lumen, increased/unchanged/shrank were 1/27/11 in 39 pts with TAAs and 6/24/15 in 45 pts with dissection.
CONCLUSION: We must follow up the fate of the false lumen and aneurysm sizes carefully in mid~late term period. We consider 2nd stage TEVAR (Hybrid TEVAR) can be a effective treatment for dissection and aneurysm cases that are estimated to grow from now on.